The half-life of the bone-derived hormone osteocalcin is regulated through O-glycosylation in mice, but not in humans

Abstract

Osteocalcin (OCN) is an osteoblast-derived hormone with pleiotropic physiological functions. Like many peptide hormones, OCN is subjected to post-translational modifications (PTMs) which control its activity. Here, we uncover O-glycosylation as a novel PTM present on mouse OCN and occurring on a single serine (S8) independently of its carboxylation and endoproteolysis, two other PTMs regulating this hormone. We also show that O-glycosylation increases OCN half-life in plasma ex vivo and in the circulation in vivo. Remarkably, in human OCN (hOCN), the residue corresponding to S8 is a tyrosine (Y12), which is not O-glycosylated. Yet, the Y12S mutation is sufficient to O-glycosylate hOCN and to increase its half-life in plasma compared to wildtype hOCN. These findings reveal an important species difference in OCN regulation, which may explain why serum concentrations of OCN are higher in mouse than in human.

Data availability

All the numerical data and the original western blots are available in the source data Excel file submitted with the manuscript. The raw proteomics data have been uploaded to a public server.

The following data sets were generated

Article and author information

Author details

  1. Omar Al Rifai

    Molecular Physiology, IRCM, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Catherine Julien

    Molecular Physiology, IRCM, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Julie Lacombe

    Molecular Physiology, IRCM, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Denis Faubert

    Proteomics Discovery Platform, IRCM, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Erandi Lira-Navarrete

    Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  6. Yoshiki Narimatsu

    Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  7. Henrik Clausen

    Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  8. Mathieu Ferron

    Molecular Physiology, IRCM, Montreal, Canada
    For correspondence
    mathieu.ferron@ircm.qc.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5858-2686

Funding

Canadian Institutes of Health Research (Operation fund,MOP-133652)

  • Mathieu Ferron

Canadian Institutes of Health Research (Project Operating fund,PJT-159534)

  • Mathieu Ferron

Natural Sciences and Engineering Research Council of Canada (Discovery grant,RGPIN-2016-05213)

  • Mathieu Ferron

Danmarks Grundforskningsfond (DNRF107)

  • Henrik Clausen

Fonds de Recherche du Québec - Santé (Doctoral scholarship)

  • Omar Al Rifai

Institut de Recherche Clinique De Montréal (Doctoral scholarship)

  • Omar Al Rifai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal use complied with the guidelines of the Canadian Committee for Animal Protection and was approved by IRCM Animal Care Committee (protocol # 2016-14 MF).

Copyright

© 2020, Al Rifai et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Omar Al Rifai
  2. Catherine Julien
  3. Julie Lacombe
  4. Denis Faubert
  5. Erandi Lira-Navarrete
  6. Yoshiki Narimatsu
  7. Henrik Clausen
  8. Mathieu Ferron
(2020)
The half-life of the bone-derived hormone osteocalcin is regulated through O-glycosylation in mice, but not in humans
eLife 9:e61174.
https://doi.org/10.7554/eLife.61174

Share this article

https://doi.org/10.7554/eLife.61174

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.

    1. Biochemistry and Chemical Biology
    Bikash Adhikari, Katharina Schneider ... Elmar Wolf
    Research Article

    The development of proteolysis targeting chimeras (PROTACs), which induce the degradation of target proteins by bringing them into proximity with cellular E3 ubiquitin ligases, has revolutionized drug development. While the human genome encodes more than 600 different E3 ligases, current PROTACs use only a handful of them, drastically limiting their full potential. Furthermore, many PROTAC development campaigns fail because the selected E3 ligase candidates are unable to induce degradation of the particular target of interest. As more and more ligands for novel E3 ligases are discovered, the chemical effort to identify the best E3 ligase for a given target is exploding. Therefore, a genetic system to identify degradation-causing E3 ligases and suitable target/E3 ligase pairs is urgently needed. Here, we used the well-established dimerization of the FKBP12 protein and FRB domain by rapamycin to bring the target protein WDR5 into proximity with candidate E3 ligases. Strikingly, this rapamycin-induced proximity assay (RiPA) revealed that VHL, but not Cereblon, is able to induce WDR5 degradation - a finding previously made by PROTACs, demonstrating its predictive power. By optimizing the steric arrangement of all components and fusing the target protein with a minimal luciferase, RiPA can identify the ideal E3 for any target protein of interest in living cells, significantly reducing and focusing the chemical effort in the early stages of PROTAC development.